Vδ1 T-cell subset appears to be responsive to PD-1 blockade therapy and is associated with survival in melanoma

Background Although most studies of anticancer T-cell immunity focus on αβ T cells, γδ T cells are attracting increasing attention due to their involvement in antitumor immune responses in various cancer entities, including melanoma. While immune checkpoint blockade (ICB) using the antagonistic prog...

Ful tanımlama

Kaydedildi:

Detaylı Bibliyografya
Asıl Yazarlar:	Susanne Sebens, Teresa Amaral, Benjamin Weide, Graham Pawelec, Thomas Eigentler, Claus Garbe, Patrick Terheyden, Friedegund Meier, Kilian Wistuba-Hamprecht, Alfred Königsrainer, Nikolaus B Wagner, Jonas Bochem, Janine Spreuer, Karolin Thiel, Can Yurttas, Daniel Soffel, Stephan Forchhammer, Markus W Löffler, Sarina Ravens, Immo Prinz, Manfred Claassen, Daniela Wesch, Nicola Herold, Johanna Leyens, Svenja Wingerter, Malte Deseke, Paola Nocerino, Rita Antunes dos Reis, Kristin Bieber, Hans-Heinrich Oberg, Shahram Kordasti
Materyal Türü:	Artigo
Dil:	Inglês
Baskı/Yayın Bilgisi:	BMJ Publishing Group 2026-01-01
Seri Bilgileri:	Journal for ImmunoTherapy of Cancer
Online Erişim:	https://jitc.bmj.com/content/14/1/e011224.full
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

Vδ1 T-cell subset appears to be responsive to PD-1 blockade therapy and is associated with survival in melanoma

Benzer Materyaller